Subscribe to RSS
DOI: 10.1055/s-0032-1308918
Gutes Ansprechen eines therapierefraktären metastasierten Malignen Melanoms auf palliative Immuntherapie mit Ipilimumab
Major Partial Response of a Recalcitrant Metastatic Malignant Melanoma to Palliative Immunotherapy with IpilimumabPublication History
Publication Date:
05 April 2012 (online)
Zusammenfassung
Wir berichten über einen 67-jährigen Patienten mit einem diffus metastasierten Malignen Melanom, das unter Chemotherapien mit Dacarbazin und Muphoran progredient verlief. Infolge einer inoperablen Tumor-Infiltration der Cardia konnte der Patient keine feste Nahrung mehr zu sich nehmen. Nach 4 Infusionen mit dem Immunmodulator Ipilimumab (Yervoy®) kam es binnen 16 Wochen zu einer deutlichen Rückbildung der Metastasen an der Cardia und in der Lunge. Der Patient war wieder in der Lage, sich normal zu ernähren.
Abstract
We report on a 67-years old male caucasian patient with diffuse metastatic malignant melanoma progressive towards chemotherapies with dacarbazine and muphoran. Because of a tumor infiltration of the cardia not suitable for surgery the patient was not able to take firm food. Following 4 infusions of the immunomodulator ipilimumab a marked regression of metastasis in the cardia and the lung was recorded within 16 weeks. The patient was able again to eat normal food.
-
Literatur
- 1 Hoos A, Ibrahim R, Korman A et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010; 37: 533-546
- 2 Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
- 3 Robert C, Thomas L, Bondarenko I et al. Ipilumumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526
- 4 Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23: 6043-6054
- 5 Hersh EM, O'Day SJ, Powderly J et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs 2011; 29: 489-498
- 6 Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12: 1005-1016